Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS), is a poorly understood, complex and debilitating disorder that severely impacts the lives of an estimated 800,000 to 2.5 million Americans, and approximately 560,000 Canadians. The underlying etiology and pathophysiology of ME are unknown and there is no diagnostic test for the disease. Consequently, there is currently no gold standard for case definition of ME.
The CHR Institute of Musculoskeletal Health and Arthritis (IMHA), in partnership with the Institute of Circulatory and Respiratory Health (ICRH) and the Institute of Infection and Immunity (III), and with the collaboration of the Institute of Neuroscience, Mental Health and Addiction (INMHA), will support a Network that will generate new knowledge to improve diagnosis and treatment of ME disease in Canada. The network will foster innovative research, build capacity, and be both a catalyst and a forum for discussing ideas, sharing best practices and consulting on challenges. Research will include efforts to define the cause(s) of the condition and test new and existing treatments for ME.
The Network is expected to be:
- national in scope — incorporating multiple research groups and researchers
- collaborative — partnering with stakeholders (not-for-profit organizations, associations, industry, provinces, etc.) and facilitating interactions between stakeholders and the scientific community (clinicians, decision makers, industry, patients, and other knowledge-users outside of the academic community)
- inclusive, multidisciplinary and multi-thematic
- committed to scientific excellence
The successful Network is encouraged to coordinate with existing initiatives in the field, to forge links with the wider community (including practitioners, policy makers and service users) and include additional partners, such as commercial or industrial representatives. More specifically, the successful Network is encouraged to coordinate with the three US-based Collaborative Research Centers (CRC) and the Data Management Coordinating Center (DMCC) funded in September 2017 by the National Institutes of Health.
In addition to funding a new research network in ME, supplementary funding may be awarded to the network for studying vascular instability and/or sleep disturbances experienced by people who live with ME (see “How to Apply” for details).
Funds Available
CIHR and partner(s) financial contributions for this initiative are subject to availability of funds. Should CIHR or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, CIHR and partner(s) reserve the right to
reduce, defer or suspend financial contributions to grants received as a result of this funding opportunity.
- The total amount available for this funding opportunity is $1,775,000.
- Of this:
- $1,400,000 is available from IMHA and III for a new research network in ME, enough to fund one (1) network grant. This amount may increase if additional funding partners participate .The maximum amount for the grant is $280,000 per year for up to five (5) years.
- $375,000 is available as supplementary funding from ICRH for the inclusion of a project addressing vascular instability and/or sleep disturbances experienced by people with ME. The maximum amount of supplementary funding is $75,000 per year for up to five (5) years.